Osimertinib Re-challenge for EGFR-mutant NSCLC after 
Osimertinib-induced Interstitial Lung Disease: A Case Report

Osimertinib Re-challenge for EGFR-mutant NSCLC after 
Osimertinib-induced Interstitial Lung Disease: A Case Report

Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in some patients. We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with o...

Full description

Bibliographic Details
Main Authors: Junjie GU, Fan BAI, Lan SONG, Yingyi WANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021-11-01
Series:Chinese Journal of Lung Cancer
Subjects:
epidermal growth factor receptor
interstitial lung disease
lung neoplasms
osimertinib
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.39

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.39

Similar Items